[1]
|
Public Health Minister of Tunisia (1999-2003) North Tunisia Cancer Register. 71.
|
[2]
|
Travis, W.D., Brambilla, E., Noguchi, M., Nicholson, A.G., Geisinger, K., Yatabe, Y., et al. (2013) Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology & Laboratory Medicine, 137, 668-684. http://dx.doi.org/10.5858/arpa.2012-0263-RA
|
[3]
|
Lee, A.L., Ng, V.W., Gao, S., Hedrick, J.L. and Yang, Y.Y. (2015) Injectable Biodegradable Hydrogels from Vitamin D-Functionalized Polycarbonates for the Delivery of Avastin with Enhanced Therapeutic Efficiency against Metastatic Colorectal Cancer. Biomacromolecules, 16, 465-475. http://dx.doi.org/10.1021/bm5015206
|
[4]
|
Kim, H.S., Lee, G.W., Kim, J.H., Kim, H.Y., Kwon, J.H., Song, H.H., Kim, H.J., Jung, J.Y., Jang, G., Choi, D.R., Park, S.M., Shin, T.R., Lee, H.S. and Zang, D.Y. (2010) A Phase II Study of Pemetrexed and Carboplatin as a Salvage Therapy for Platinum-Pretreated Patients with Non-Small Cell Lung Cancer. Lung Cancer, 70, 71-76.
http://dx.doi.org/10.1016/j.lungcan.2009.12.015
|
[5]
|
Pao, W., Wang, T.Y., Riely, G.J., et al. (2005) KRAS Mutations and Primary Resistance of Lung Adenocarcinoma to Gefitinib or Erlotinib. PLoS Medicine, 2, e17. http://dx.doi.org/10.1371/journal.pmed.0020017
|
[6]
|
Adamson, R.T. (2013) Biomarkers and Molecular Profiling in Non-Small Cell Lung Cancr: An Expanding Role and Its Managed Care Implications. American Journal of Managed Care, 19, S398-S407.
|
[7]
|
Hynes, N.E. and Lane, H.A. (2005) ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors. Nature Reviews Cancer, 5, 341-354. http://dx.doi.org/10.1038/nrc1609
|
[8]
|
Suda, K., Tomizawa, K. and Mitsudomi, T. (2010) Biological and Clinical Significance of KRAS Mutations in Lung Cancer: An Oncogenic Driver That Contrasts with EGFR Mutation. Cancer and Metastasis Reviews, 29, 49-60.
http://dx.doi.org/10.1007/s10555-010-9209-4
|
[9]
|
Carr, L.L., Finigan, J.H. and Kern, J.A. (2011) Evaluation and Treatment of Patients with Non-Small Cell Lung Cancer. Medical Clinics of North America, 95, 1041-1054. http://dx.doi.org/10.1016/j.mcna.2011.08.001
|
[10]
|
Mitsudomi, T. and Yatabe, Y. (2007) Mutations of the Epidermal Growth Factor Receptor Gene and Related Genes as Determinants of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Sensitivity in Lung Cancer. Cancer Science, 98, 1817-1824. http://dx.doi.org/10.1111/j.1349-7006.2007.00607.x
|
[11]
|
Berardi, R., Santoni, M., Morgese, F., Ballatore, Z., Savini, A., Onofri, A., et al. (2013) Novel Small Molecule EGFR Inhibitors as Candidate Drugs in Non-Small Cell Lung Cancer. OncoTargets and Therapy, 6, 563-576.
http://dx.doi.org/10.2147/OTT.S28155
|
[12]
|
Cataldo, V.D., Gibbons, D.L., Pérez-Soler, R. and Quintás-Cardama, A. (2011) Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine, 364, 947-955.
http://dx.doi.org/10.1056/NEJMct0807960
|
[13]
|
Mao, C., Qiu, L.X., Liao, R.Y., Du, F.B., Ding, H., Yang, W.C., et al. (2010) KRAS Mutations and Resistance to EGFR-TKIs Treatment in Patient with Non-Small Cell Lung Cancer: A Meta-Analysis of 22 Studies. Lung Cancer, 69, 272-278. http://dx.doi.org/10.1016/j.lungcan.2009.11.020
|
[14]
|
Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007) Identification of the Transforming EML4-ALK Fusion Gene in Non-Small-Cell Lung Cancer. Nature, 448, 561-566.
http://dx.doi.org/10.1038/nature05945
|
[15]
|
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., et al. (2007) Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell, 131, 1190-1203.
http://dx.doi.org/10.1016/j.cell.2007.11.025
|
[16]
|
Takeuchi, K., Choi, Y.L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., et al. (2009) KIF5B-ALK, a Novel Fusion Oncokinase Identified by Immunohistochemistry-Based Diagnostic System for ALK-Positive Lung Cancer. Clinical Cancer Research, 15, 3143-3149. http://dx.doi.org/10.1158/1078-0432.CCR-08-3248
|
[17]
|
Pan, Y., Zhang, Y., Li, Y., Hu, H., Wang, L., Li, H., Wang, R., Ye, T., et al. (2014) ALK, ROS1 and RET Fusions in 1139 Lung Adenocarcinomas: A Comprehensive Study of Common and Fusion Pattern-Specific Clinicopathologic, Histologic and Cytologic Features. Lung Cancer, 84, 121-126.
http://dx.doi.org/10.1016/j.lungcan.2014.02.007
|
[18]
|
Bepler, G., Zinner, R.G., Moon, J., Calhoun, R., Kernstine, K., Williams, C.C., et al. (2014) A Phase 2 Cooperative Group Adjuvant Trial Using a Biomarker-Based Decision Algorithm in Patients with Stage I Non-Small Cell Lung Cancer (SWOG-0720, NCT00792701). Cancer, 120, 2343-2351. http://dx.doi.org/10.1002/cncr.28714
|
[19]
|
Dong, X., Hao, Y., Wei, Y., Yin, Q., Du, J. and Zhao, X. (2014) Response to First-Line Chemotherapy in Patients with Non-Small Cell Lung Cancer According to RRM1 Expression. PLoS ONE, 9, e92320.
http://dx.doi.org/10.1371/journal.pone.0092320
|
[20]
|
Jürgens, J., Engel-Riedel, W., Prickartz, A., Ludwig, C., Schildgen, O., Tillmann, R.L., et al. (2014) Combined Point Mutation in KRAS or EGFR Genes and EML4-ALK Translocation in Lung Cancer Patients. Future Oncology, 10, 529-532. http://dx.doi.org/10.2217/fon.13.194
|
[21]
|
Azijli, K., van Roosmalen, I.A., Smit, J., Pillai, S., Fukushima, M., de Jong, S., et al. (2014) The Novel Thymidylate Synthase Inhibitor Trifluorothymidine (TFT) and TRAIL Synergistically Eradicate Non-Small Cell Lung Cancer Cells. Cancer Chemotherapy and Pharmacology, 73, 1273-1283. http://dx.doi.org/10.1007/s00280-014-2465-1
|
[22]
|
Murgu, S. and Colt, H. (2013) Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non-Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 14, 609-626.
http://dx.doi.org/10.1016/j.cllc.2013.04.002
|
[23]
|
Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., et al. (2013) Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 8, 823-859. http://dx.doi.org/10.1097/JTO.0b013e318290868f
|
[24]
|
Murakami, Y., Mitsudomi, T. and Yatabe, Y. (2012) A Screening Method for the ALK Fusion Gene in NSCLC. Frontiers in Oncology, 2, 24. http://dx.doi.org/10.3389/fonc.2012.00024
|
[25]
|
Institut National du Cancer (INCA). Rapport Scientifique 2010-2011.
|
[26]
|
Coate, L.E. and Leighl, N.B. (2011) How Affordable Are Targeted Therapies in Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 12, 1-11. http://dx.doi.org/10.1007/s11864-010-0137-x
|
[27]
|
Rapport budget année 2013 Ministère de la Santé. République Tunisienne. 3-4.
|
[28]
|
Lewis, J.R., Lipworth, W.L., Kerridge, I.H. and Day, R.O. (2013) The Economic Evaluation of Personalized Oncology Medicines: Ethical Challenges. Medical Journal of Australia, 199, 471-473.
|